Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)

The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second- or third-line treatment for elderly Japanese patients with non-small-cell lung cancer (NSCLC). The patients eligible for this phase II tria...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Clin Oncol
Main Authors: Miyawaki, Masayoshi, Naoki, Katsuhiko, Yoda, Satoshi, Nakayama, Sohei, Satomi, Ryosuke, Sato, Takashi, Ikemura, Shinnosuke, Ohgino, Keiko, Ishioka, Kota, Arai, Daisuke, Namkoong, Ho, Otsuka, Kengo, Miyazaki, Masaki, Tani, Tetsuo, Kuroda, Aoi, Nishino, Makoto, Yasuda, Hiroyuki, Kawada, Ichiro, Koh, Hidefumi, Nakamura, Morio, Terashima, Takeshi, Sakamaki, Fumio, Sayama, Koichi, Betsuyaku, Tomoko, Soejima, Kenzo
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5403701/
https://ncbi.nlm.nih.gov/pubmed/28451422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1154
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados